Innovent Biologics Inc. announced June 27 that it gained National Medical Products Administration’s (NMPA) approval of mazdutide as a new weight loss therapy for obese or overweight patients in China. Mazdutide is a dual glucagon/glucagon-like peptide-1 (GCG/GLP-1) receptor agonist originally discovered by Eli Lilly and Co., of Indianapolis.
MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.
IBI-3030 from Innovent Biologics Inc. is a novel antibody-peptide conjugate targeting PCSK9 that shows agonism for GLP-1R, GCGR and GIPR, aimed to confer therapeutic benefit against cardiovascular disease.
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of physical exercise by activating skeletal muscle metabolism. Unlike GLP-1-based treatments such as semaglutide and tirzepatide, this new compound, developed by researchers at the Karolinska Institute, Stockholm University, and the biotech company Atrogi AB, does not suppress appetite or cause muscle loss.
Mira Pharmaceuticals Inc. has reported new in vitro preclinical data supporting the therapeutic potential of SKNY-1, a next-generation oral drug candidate being developed by Skny Pharmaceuticals Inc.
Amylin is an attractive target in the management of obesity, since it is a peptide hormone co-secreted with insulin in response to food intake, and suppresses appetite and delays gastric emptying. At the American Diabetes Association's Scientific Sessions in Chicago, Structure Therapeutics Inc. presented data regarding the dual amylin receptor and calcitonin receptor agonist ACCG-2671 for obesity treatment.
Supercede Therapeutics Inc. has released preclinical efficacy data on its small-molecule inhibitor of the Activin receptor type II (ACTRII) to treat obesity.
Biomea Fusion Inc. has released preclinical findings from a 28-day weight loss study in obese nonhuman primates evaluating BMF-650, a next-generation oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1RA).
Ibio Inc. has nominated IBIO-610 as a development candidate for its first-in-class Activin E antibody program and initiated a nonhuman primate (NHP) study.
MBX Biosciences Inc. has submitted an IND application to the FDA for MBX-4291, a long-acting glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonist prodrug for the treatment of obesity.
